BiotechTube
Home/Alar Pharmaceuticals/Yung‑Shun Wen, Ph.D.
YW

Yung‑Shun Wen, Ph.D.

CEO

Alar Pharmaceuticals

Therapeutic Areas

CNS DisordersChronic PainOsteoarthritis

Alar Pharmaceuticals Pipeline

DrugIndicationPhase
ALA-3000Treatment‑Resistant DepressionPhase 1
ALA-1000Osteoarthritis‑Associated Pain (Veterinary)Animal Drug
ALA-1300CNS Disorder (Preclinical)Preclinical
ALA-2000CNS Disorder (Preclinical)Preclinical
BupanlarLong‑Acting Osteoarthritis Analgesic (Veterinary)Animal Drug

Leadership Team at Alar Pharmaceuticals

CL
Charles Lin
Chairman of the Board
VK
Vivian Kang
Director of Finance
View full Alar Pharmaceuticals profile